FDA accepts Feraheme response

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) said FDA accepted the company's response to a December complete response letter for Feraheme ferumoxytol to treat iron deficiency anemia in patients with chronic kidney disease (CKD). The agency designated the response as a class 1 resubmission, with a PDUFA date of June 29. ...